Heidi Elliot

Betibeglogene Autotemcel Gene Therapy for Non–β ⁰ /β ⁰ Genotype β-Thalassemia

Franco Locatelli, Alexis A. Thompson, Janet L. Kwiatkowski et al. · New England Journal of Medicine · 2021 · 258 citations · Full text

Medicine, Hematology, Pharmacokinetics +17

HYPERCALCAEMIC OSTEOMALACIA DUE TO ALUMINIUM TOXICITY

B.F. Boyce, H. Y. Elder, Heidi Elliot et al. · The Lancet · 1982 · 167 citations

Medicine, Toxicology, Bone Metabolism +9

Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial

Janet L. Kwiatkowski, Mark C. Walters, Suradej Hongeng et al. · The Lancet · 2024 · 38 citations

Medicine, Hematology, Pharmacology +13

Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene

Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski et al. · Blood · 2019 · 25 citations

Medicine, Genetics, Hematology +13

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Julie Kanter, Alexis A. Thompson, Janet L. Kwiatkowski et al. · Blood · 2023 · 15 citations

Medicine, Hematology, Translational Sciences +14